Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Business Wire
Jakavi® (ruxolitinib) is the first JAK1/2 inhibitor available for patients in Europe who previously had no approved therapies for the treatment of steroid-refractory graft-versus-host disease (GVHD)1,2In clinical trials, Jakavi demonstrated superiority versus best available therapy in patients with steroid-refractory/dependent acute and chronic GVHD, with overall response rates of 62% vs. 39%, and 50% vs. 26% respectively2,3GVHD is a common and potentially life-threatening complication that arises in approximately half of patients following allogeneic stem cell transplants4 WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced the European Commission (EC) has approved Jakavi® (ruxolitinib) for the treatment of patients aged 12 years and older with acute or chronic GVHD who have inadequate response to corticosteroids or other systemic therapies. Ruxolitinib is marketed as Jakavi by Novartis in Europe and as Jakafi® by Incyte in the United States.“With the approval
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Co. (NASDAQ: INCY) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $92.00 to $84.00. They now have an "outperform" rating on the stock.MarketBeat
- Incyte (INCY) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- Incyte to acquire immune-focused drug developer Escient [Seeking Alpha]Seeking Alpha
- Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists [Yahoo! Finance]Yahoo! Finance
- Incyte Co. (NASDAQ: INCY) is now covered by analysts at Cantor Fitzgerald. They set a "neutral" rating on the stock.MarketBeat
INCY
Earnings
- 2/13/24 - Beat
INCY
Sec Filings
- 4/2/24 - Form 4
- 4/2/24 - Form 4
- 4/1/24 - Form 4
- INCY's page on the SEC website